Gut microbiome of a porcine model of metabolic syndrome and HF-pEF

被引:22
|
作者
O'Donovan, Aoife N. [1 ,2 ,3 ]
Herisson, Florence M. [3 ,5 ]
Fouhy, Fiona [1 ,3 ]
Ryan, Paul M. [5 ]
Whelan, Derek [5 ]
Johnson, Crystal N. [1 ,3 ]
Cluzel, Gaston [3 ,5 ]
Ross, R. Paul [3 ,4 ]
Stanton, Catherine [1 ,3 ]
Caplice, Noel M. [3 ,5 ]
机构
[1] Teagasc Food Res Ctr, Moorepk, Cork, Ireland
[2] Univ Coll Cork, Sch Microbiol, Cork, Ireland
[3] Univ Coll Cork, APC Microbiome Ireland, Cork, Ireland
[4] Univ Coll Cork, Coll Sci Engn & Food Sci, Cork, Ireland
[5] Univ Coll Cork, Ctr Res Vasc Biol, Cork, Ireland
基金
爱尔兰科学基金会;
关键词
cardiometabolic syndrome; gut microbiome; pig; AMERICAN-SOCIETY; AKKERMANSIA-MUCINIPHILA; CHAMBER QUANTIFICATION; EUROPEAN-ASSOCIATION; SERUM-CHOLESTEROL; FECAL MICROBIOTA; HEART-FAILURE; FATTY-ACIDS; BILE-ACIDS; RECOMMENDATIONS;
D O I
10.1152/ajpheart.00512.2019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Metabolic syndrome (MetS) is a composite of cardiometabolic risk factors, including obesity. dyslipidemia, hypertension, and insulin resistance, with a range of secondary sequelae such as nonalcoholic fatty liver disease and diastolic heart failure. This syndrome has been identified as one of the greatest global health challenges of the 21st century. Herein, we examine whether a porcine model of diet- and mineralocorticoid-induced MetS closely mimics the cardiovascular, metabolic, gut microbiota, and functional metataxonomic phenotype observed in human studies. Landrace pigs with deoxycorticosterone acetate-induced hypertension fed a diet high in fat, salt, and sugar over 12 wk were assessed for hyperlipidemia, hyperinsulinemia, and immunohistologic. echocardiographic. and hemodynamic parameters, as well as assessed for microbiome phenotype and function through 16S rRNA metataxonomic and metabolomic analysis, respectively. All MetS animals developed obesity, hyperlipidemia, insulin resistance. hypertension, fatty liver, structural cardiovascular changes including left ventricular hypertrophy and left atrial enlargement, and increased circulating saturated fatty acid levels, all in keeping with the human phenotype. A reduction in a-diversity and specific microbiota changes at phylum, family, and genus levels were also observed in this model. Specifically, this porcine model of MetS displayed increased abundances of prointlammatory bacteria coupled with increased circulating tumor necrosis factor-a and increased secondary bile acid-producing bacteria, which substantially impacted fibroblast growth factor-19 expression. Finally, a significant decrease in enteroprotective bacteria and a reduction in short-chain fatty acid-producing bacteria were also noted. Together, these data suggest that diet and mineralocorticoidmediated development of biochemical and cardiovascular stigmata of metabolic syndrome in pigs leads to temporal gut microbiome changes that mimic key gut microbial population signatures in human cardiometabolic disease. NEW & NOTEWORTHY This study extends a prior porcine model of cardiometabolic syndrome to include systemic inflammation, fatty liver, and insulin sensitivity. Gut microbiome changes during evolution of porcine cardiometabolic disease recapitulate those in human subjects with alterations in gut taxa associated with proinflatnmatory bacteria, bile acid. and fatty acid pathways. This clinical scale model may facilitate design of future interventional trials to test causal relationships between gut dysbiosis and cardiometabolic syndrome at a systemic and organ level.
引用
收藏
页码:H590 / H603
页数:14
相关论文
共 50 条
  • [1] Clinical pattern of HF-pEF and role of comorbidity in development of HF-pEF
    Dubolazova, Y.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 506 - 506
  • [2] Imaging in HF-PEF with Cardiovascular Magnetic Resonance
    Hinojar R.
    Fernández-Golfín C.
    Zamorano J.L.
    Current Cardiovascular Imaging Reports, 2015, 8 (3)
  • [3] HFNEF, HFpEF, HF-PEF, or DHF What Is in an Acronym?
    Sanderson, John E.
    JACC-HEART FAILURE, 2014, 2 (01) : 93 - 94
  • [4] ACE INHIBITORS AND OUTCOMES IN OLDER HF-PEF PATIENTS
    Ahmed, A.
    GERONTOLOGIST, 2012, 52 : 722 - 722
  • [5] ALDOSTERONE ANTAGONISTS AND OUTCOMES IN OLDER HF-PEF PATIENTS
    Patel, K.
    GERONTOLOGIST, 2012, 52 : 722 - 722
  • [6] BETA-BLOCKERS AND OUTCOMES IN OLDER HF-PEF PATIENTS
    Ahmed, A.
    GERONTOLOGIST, 2012, 52 : 722 - 722
  • [7] Registry data highlight global differences in care for HF-PEF
    Alexandra King
    Nature Reviews Cardiology, 2011, 8 (9) : 482 - 482
  • [8] ANGIOTENSIN RECEPTOR BLOCKERS AND OUTCOMES IN OLDER HF-PEF PATIENTS
    Patel, K.
    GERONTOLOGIST, 2012, 52 : 722 - 722
  • [9] Gut microbiome and metabolic syndrome
    Mazidi, Mohsen
    Rezaie, Peyman
    Kengne, Andre Pascal
    Mobarhan, Majid Ghayour
    Ferns, Gordon A.
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2016, 10 (02) : S150 - S157
  • [10] The gut microbiome and metabolic syndrome
    Dabke, Kruttika
    Hendrick, Gustaf
    Devkota, Suzanne
    JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (10): : 4050 - 4057